However, the peptides effects on fat metabolism may theoretically interact with diabetes medications, insulin, or other compounds affecting glucose and lipid metabolism
Ozempic (semaglutide) was approved by the FDA in December 2017 for type 2 diabetes, and in 2021 the company introduced a higher-dose version of semaglutide, branded as Wegovy, that was approved specifically for weight management
Women in perimenopause and menopause are becoming a large percentage of GLP-1 users because hormonal changes often make weight management more difficult than it used to be
When platforms normalize breaks and celebrate consistency over volume, players benefit
The honest answer: Medicare doesn't pay for compounded GLP-1 weight-loss medication itself, but it often helps cover the care around it your provider visits, monitoring, lab testing, and continuous glucose monitors for those who qualify